In addition, although our recent study has proven that Ccndbp1 can be a therapeutic target in hepatocellular carcinoma with poor response to conventional therapy [11], additional basic and clinical research is necessary to further gather important information using the specific inhibitors of the Atm–Chk2 pathway. This evidence concerns the gene CHEK2 and hepatocellular carcinoma.